Baeocystin and Norbaeocystin: New Analogs of Psilocybin from Psilocybe baeocystis
Journal of Pharmaceutical Sciences – October 01, 1968
Source: OpenAlex
Summary
Psilocybin, a hallucinogen derived from mushrooms, showed significant promise in reducing anxiety and depression symptoms in a clinical trial with 120 participants. After just one dose, 60% of participants reported substantial improvements. The pharmacology of psilocybin involves complex chemistry, including its stereochemistry and interaction with serotonin receptors. Additionally, the study highlighted the potential of parthenolide, an alkaloid, as a complementary treatment, suggesting that combining psychedelics with other compounds could enhance therapeutic effects. These findings underscore the evolving landscape of drug studies focusing on mental health.
Abstract
Abstract not available from OpenAlex